Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (MINI HEME)

Inclusion Criteria - Patient:

• AML, ALL,CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL, MDS, RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA, Aplastic Anemia, Multiple Myeloma, MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET
• Age less than 65 years
• Patients must have a healthy family member who is HLA-identical to the recipient or has 1 antigen mismatch and who is willing to receive a course of G-CSF and undergo 2-4 daily leukaphereses
• Each patient must sign an informed consent and be willing to participate as a research subject after having been advised of the nature and risk of the study prior to entering protocol

Inclusion Criteria - Donor:

• Absence of hematologic or marrow function related diseases that interferes with the collection of sufficient numbers of normal progenitor cells
• Absence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest
• Negative HIV, HTLV-1, Hepatitis B surface antigen and Hepatitis C
• The donor must be blood relation. A prospective related donor must be at least genotypically HLA-A, B, DR identical to the patient, but can differ for 1 HLA-locus.

Exclusion Criteria - Patient:

• Active CNS involvement
• Females who are pregnant or breast feeding
• ECOG performance status > 1. Karnofsky performance status < 80%
• LVEF < 40%
• Active viral, bacterial, or fungal infection
• Patients seropositive for HIV; HTLV -1
• Patients not providing informed consent
• Patients with known hypersensitivity to E. Coli derived product

Exclusion Criteria - Donor:

• A positive HIv infection or HTLV - 1 test or evidence of active/persistent viral hepatitis infection. Presence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest. Donors with known hypersensitivity to E. Coli derived products.